Home Business ICER unsure about cost-effectiveness of argenx’s efgartigimod for myasthenia gravis

ICER unsure about cost-effectiveness of argenx’s efgartigimod for myasthenia gravis

13
0

ICER unsure about cost-effectiveness of argenx's efgartigimod for myasthenia gravis

LEAVE A REPLY

Please enter your comment!
Please enter your name here